☆ 4.7 Article

Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Related references

Note: Only part of the references are listed.

Letter Medicine, General & Internal

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Sophie Caillard et al.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Markus Hoffmann et al.

Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.

CELL (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients

Binu V. John et al.

GASTROENTEROLOGY (2022)

Add to Collection

Article Surgery

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients

Marta Kantauskaite et al.

Summary: Kidney transplant recipients (KTRs) have a weaker immune response to SARS-CoV-2 vaccination compared to controls, with mycophenolate mofetil (MMF) treatment being the strongest predictor for impaired response. Adjusting MMF dose may improve the immune response in KTRs.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Gastroenterology & Hepatology

SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients

Darius F. Ruether et al.

Summary: Detailed information on the immune response after second vaccination of cirrhotic patients and liver transplant recipients against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is largely missing. We aimed at comparing the vaccine-induced humoral and T-cell responses of these vulnerable patient groups. After the second vaccination, seroconversion was achieved in 63% of LT recipients and 100% of cirrhotic patients and controls using the anti-S trimer assay. Spike-specific T-cell response rates were 36.6%, 65.4%, and 100% in LT, cirrhosis, and controls, respectively.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Surgery

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Louise Benning et al.

Summary: Seroconversion after COVID-19 vaccination is compromised in kidney transplant recipients, and emerging variants pose an increasing threat to these patients. Following a third vaccine dose, neutralizing antibodies in kidney transplant recipients are significantly lower compared to healthy controls, with reduced efficacy against the B.1.1.529 (omicron) variant.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!

Maria Guarino et al.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients

Pierluigi Toniutto et al.

Summary: This study explores the long-term antibody response and failure mechanism of COVID-19 vaccines in liver transplant recipients, revealing significantly lower antibody titers after vaccination compared to controls and identifying MMF as a major predictor of vaccination failure.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients

Yana Davidov et al.

Summary: Liver transplant recipients showed significantly improved immune response after receiving a third dose of the BNT162b2 mRNA vaccine. The majority of patients developed sufficient humoral and cellular immune responses. Older age and immunosuppressive medications were predictive factors for non-response.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients

Lucy Meunier et al.

Summary: The response rate to anti-SARS-CoV-2 vaccination is lower in liver transplant recipients, even after a booster dose. Mycophenolate mofetil is a major determinant of vaccine effectiveness in these patients.

LIVER INTERNATIONAL (2022)

Add to Collection

Article Gastroenterology & Hepatology

Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients

Antonio Cuadrado et al.

Summary: Most liver transplant recipients develop an immunological response to the Moderna SARS-CoV-2 mRNA-based vaccine, while an immunosuppressive regimen that includes mycophenolate predicts a weaker serologic response.

HEPATOLOGY COMMUNICATIONS (2022)

Add to Collection

Article Urology & Nephrology

B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients

Eva Schrezenmeier et al.

Summary: The study found that 36% of kidney transplant recipients showed seroconversion after receiving a third dose of vaccine, highlighting the need for individual humoral monitoring and continued efforts to adapt vaccination protocols for immunosuppressed individuals. The quantitative and qualitative changes in cellular immunity associated with seroconversion emphasize the importance of modified vaccination approaches for this at-risk group.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda et al.

Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study

Benaya Rozen-Zvi et al.

Summary: Kidney transplant recipients showed a low antibody response rate of 36.4% after receiving the SARS-CoV-2 mRNA vaccine. Factors associated with antibody response include estimated glomerular filtration rate, medication dosage, age, and calcineurin inhibitor blood level.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Gastroenterology & Hepatology

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Liane Rabinowich et al.

Summary: Liver transplant recipients showed significantly lower immunological response to the Pfizer-BioNTech SARS-CoV-2 mRNA-based vaccine, with less than half developing sufficient levels of antibodies and lower average antibody levels compared to healthy controls. Predictors for non-response included older age, renal function and immunosuppressive medications.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant

Nassim Kamar et al.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Virology

Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay

Katarina Resman Rus et al.

Summary: The study compared Elecsys Anti-SARS-CoV-2 S (Elecsys-S) with neutralization tests (NT) for detecting and quantifying anti-SARS-CoV-2 neutralizing antibodies (NAb). Elecsys-S showed a high detection rate of pan-anti-S1-RBD-SARS-CoV-2 antibodies and moderate agreement with NT results.

JOURNAL OF CLINICAL VIROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases

Paul J. Thuluvath et al.

Summary: The study found that 61% of liver transplant recipients and 24% of patients with liver disease had poor antibody responses after receiving the SARS-CoV-2 vaccine. Immunocompromised status, vaccination with a single dose of Johnson & Johnson vaccine, and use of 2 or more immunosuppressive medications were associated with poor immune responses.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Letter Urology & Nephrology

A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse

Timm H. Westhoff et al.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Immunology

Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant

Julian Stumpf et al.

TRANSPLANTATION (2021)

Add to Collection

Article Microbiology

Broadly directed SARS-CoV-2-specific CD4+T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19

Janna Heide et al.

Summary: The study aimed to explore the CD4+ T cell response to SARS-CoV-2 and found a universally broad T cell response in patients, identifying multiple specific peptides. These findings are important for understanding the immunopathogenesis of SARS-CoV-2 infection and vaccine design.

PLOS PATHOGENS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Gwilym J. Webb et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.